Skip to main content
Journal of Traditional Chinese Medicine logoLink to Journal of Traditional Chinese Medicine
. 2026 Oct 9;46(5):1127–1138. doi: 10.19852/j.cnki.jtcm.2026.05.007

Bushen Huoxue decoction (补肾活血汤) attenuates osteoporosis in ovariectomized rats through suppressing osteoclast differentiation by targeting sirtuin 1 to deactivate nuclear factor-κB

Shuai CHEN 1,#, Jie JIN 1,#, Yuwen HU 2, Ningsheng TIAN 1, Huawei HAN 1, Ziqing XU 1, Lan WU 3,✉, Zhiwei LI 1,✉
PMCID: PMC13684367  PMID: 42958664

Abstract

OBJECTIVE:

To investigate the anti-osteoporotic effects of Bushen Huoxue decoction (补肾活血汤, BSHXD) and its underlying molecular mechanisms in a postmenopausal osteoporosis (PMOP) model.

METHODS:

The model of PMOP was established by bilateral ovariectomy in female rats, and each group were given different doses of BSHXD, or Alendronate by oral gavage. Then, the therapeutic effect of BSHXD on PMOP was estimated using micro-CT analysis, histological staining, and immunohistochemical analysis. In vitro experiment, immunofluorescence analysis, luciferase assay, and co-immunoprecipitation (Co-IP) were used to examine the potential impact and mechanism of BSHXD on osteoclast differentiation. Additionally, Sirtinol was employed to silence Sirt1 and further investigate its involvement in the protective effects of BSHXD.

RESULTS:

Our study demonstrated that BSHXD ameliorates bone loss and improves trabecular microstructure in osteoporosis model rats. Simultaneously, histological analysis revealed that BSHXD treatment led to a downregulation of tartrate-resistant acid phosphatase (Trap), matrix metalloproteinase 9, and nuclear factor of activated T cells cytoplasmic 1 expression. In addition, the in vitro experiment provided evidence that BSHXD effectively inhibits the formation of osteoclasts and reduces Trap positive osteoclasts. Luciferase assay and CO-IP analysis revealed that BSHXD decreases the acetylation level of nuclear factor NF-kappa-B p65 subunit (p65) and suppresses the activity of nuclear factor-κB (NF-κB), and significantly promotes the binding of Sirtuin 1 (Sirt1) to p65. Notably, after administration with the Sirt1 inhibitor, the antiosteoporotic effect of BSHXD was reduced and NF‐κB activity was increased.

CONCLUSION:

BSHXD promoted p65 deacetylation by activating Sirt1, thereby inhibiting the NF-κB pathway and subsequently alleviating osteoclast differentiation and bone resorption.

Keywords: osteoporosis, postmenopausal; osteoclasts; Sirtuin 1; acetylation; Bushen Huoxue decoction

1. INTRODUCTION

Postmenopausal osteoporosis (PMOP) is a metabolic bone disease characterized by decreased bone mass, bone microstructure destruction, and increased bone fragility due to insufficient estrogen secretion in postmenopausal women.1,2 As the global population ages, the prevalence of PMOP is constantly rising, affecting approximately 30% of postmenopausal women in the United States and Europe, which brings a substantial challenge to patients’ families and social health care.3 Currently, bisphosphonates, denosumab, and estrogen receptor drugs are commonly employed in the clinical management of PMOP.4 Nevertheless, the long-term use of these drugs has been associated with potential adverse effects, including gastrointestinal discomfort, atypical subtrochanteric fractures, and hypocalcemia.5-7 Consequently, it is imperative to develop safe and effective treatment options that can reduce or replace the reliance on these presently used drugs.

After menopause, the decrease in estrogen levels disrupts the equilibrium between bone formation and bone absorption during bone metabolism,8 and the over-activation of osteoclasts further contributes to the progression of PMOP.9 Osteoclasts are derived from the differentiation of monocytes stimulated by receptor activator for nuclear factor-κB ligand (RANKL) and macrophage colony stimulating factor (M-CSF).10 Estrogen deficiency results in an increased production of RANKL by osteoblasts and bone marrow stromal cells, which induces and increases osteoclastogenesis. When M-CSF is present, the receptor RANK recruits the tumour necrosis factor receptor associated factor 6 (TRAF6) by binding to its ligand RANK,11-12 thereby triggering various downstream signaling, including nuclear factor-κB (NF-κB), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinases (MAPKs). Following RANKL stimulation, the NF-κB inhibitor kinase (IKKs) is activated and activated IKKs (IKKα and IKKβ) lead to inhibitor of nuclear factor kappa-B alpha (IκBα) phosphorylation and nuclear factor NF-kappa-B p65 subunit (p65) translocation to the nucleus, which ultimately triggers the NF-κB signaling pathway.13 Subsequently, this event promotes the activation of nuclear factor of activated T cells 1 (NFATc1), which activates osteoclast-related genes, such as tartrate-resistant acid phosphatase (Trap), matrix metalloproteinase 9 (MMP9), cathepsin K (CTSK), and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) itself.11 There are complex and highly regulated mechanisms for NF-кB activity, in which acetylation of the p65 subunit is a significant factor in regulating its transcriptional activity.14 There is evidence that Sirtuin 1 (Sirt1) is an nicotinamide adenine dinucleotide (NAD)+-dependent histone deacetylase that binds to acetyltransferase p300 and prevents acetylation of p65, thus inhibiting the NF-κB pathway and subsequently suppressing osteoclastogenic differentiation.15 In addition, Sirt1 has been demonstrated to play a pivotal role in regulating bone homeostasis by suppressing osteoclastogenesis and promoting osteogenic differentiation and mineralization.16 Therefore, targeting Sirt1 to inhibit NF-κB activation could serve as a potential treatment mechanism for PMOP.

In accordance with the Traditional Chinese Medicine (TCM) theory, PMOP belongs to the category of “Guwei”, in which kidney deficiency and blood stasis are identified as the core pathogenesis. Bushen Huoxue decoction (补肾活血汤, BSHXD) is a classic prescription derived from Shang Ke Da Cheng,17 which has been widely used for several decades to treat osteoporosis in China and produced satisfactory clinical outcomes. This prescription is renowned for its ability to tonify the kidney and enhance the bone, stimulate blood circulation and relieve pain.18 Several clinical trials have provided evidences indicating that BSHXD could increase estrogen levels, improve bone metabolism, and enhance fracture healing.19-21 Additionally, Chen et al 22 demonstrated that BSHXD treatment can effectively attenuate inflammatory bone loss in mice by inhibiting the polarization of M1 macrophages. Despite these findings, the action targets and specific molecular mechanisms of BSHXD in the treatment of PMOP remains unknown. Therefore, this study aims to evaluate the influence of BSHXD on osteoporosis model rats induced by ovariectomized (OVX) and to investigate whether its mechanism involves the attenuation of bone resorption via Sirt1-mediated deacetylation of p65.

2. MATERIALS AND METHODS

2.1. Preparation of BSHXD

BSHXD is an herbal decoction composed of 11 traditional Chinese plants: Shudihuang (Radix Rehmanniae Praeparata, 9 g), Duzhong (Cortex Eucommiae, 3 g), Gouqizi (Fructus Lycii, 3 g), Buguzhi (Fructus Psoraleae, 9g), Tusizi (Semen Cuscutae, 9 g), Danggui (Radix Angelicae Sinensis, 3 g), Moyao (Myrrh, 3 g), Shanzhuyu (Fructus Macrocarpii, 3 g), Honghua (Flos Carthami, 1.5 g), Duhuo (Radix Angelicae Biserratae, 3 g), and Roucongrong (Herba Cistanches Deserticolae, 3 g). All herbs were sourced from the Second Affiliated Hospital of Nanjing University of Chinese Medicine (Nanjing, China) and authenticated by Professor Haiyan Qian. The medicinal herbs were soaked in 10 times of water (w/v) for 1 h. They were brought to a boil and simmered for 1 h before filtering out the liquid. Then 8 times the volume of water was added to the residue, and the simmering process was repeated for 30 min before filtering. The combined filtrates were collected and subsequently concentrated at 2 g crude drug/mL.

2.2. High performance liquid chromatography (HPLC)

The qualitative chemical profile of BSHXD was analyzed by HPLC. The mobile phase A was 0.1% formic acid and the mobile phase B was acetonitrile. The temperature of the chromatographic column was 35 ℃, the detection wavelength was 335 nm, the flow rate was 1 mL/min, and the sample volume was 10 μL. The gradient elution was 0-5 min (2% B), 5-20 min (2%-5% B), 20-63 min (5%-15% B), 63-110 min (15%-35% B).

2.3. Animals

In this experiment, sixty female Sprague-Dawley rats (12-weeks-old) were purchased from the Zhejiang Provincial Experimental Animal Center (Certificate of quality No. SCXK [jing] 2019-0010). They were housed in an environment maintained at a temperature of (20 ± 2) ℃. The rats were exposed to a 12 h diurnal cycle each day. Throughout the duration of the study, rats were provided with unlimited access to both food and water. The Animal Experiment Ethics Committee of Nanjing University of Chinese Medicine approved the animal experiments (Registration number: No. 202304A067; Registration date: 2023-04-08).

2.4. Animal grouping and treatment

Rats were randomly divided into six groups (n = 10): Sham group (Sham), OVX group (OVX), OVX + low dose BSHXD group (BSHXD-L), OVX + medium dose BSHXD group (BSHXD-M), OVX + high dose BSHXD group (BSHXD-H), and OVX + positive group (Alendronate). Alendronate sodium (Approval No. National Pharmaceutical Standard J20130085) was purchased from Hangzhou Merck Pharmaceutical Co., Ltd. (Hangzhou, China). After a 7-d period of acclimatization, all rats received intraperitoneal injections of pentobarbital sodium (40 mg/kg, 100 g/mL) dissolved in physiological saline. Abdominal incisions were made, and in the Sham group, only the surrounding fat tissue was removed before closing the abdomen. In the other groups, ovariectomy surgeries were performed. After surgery, all rats received penicillin injections for infection prevention for three consecutive days. Vaginal smears were observed for three days, which demonstrated that rats in the ovariectomy groups showed no estrous cycle, confirming the success of ovariectomy.

After confirming the successful molding, intragastric administration was initiated. The dose of administration was converted according to half, one or two times of the clinical human dose.23 The low-dose, medium-dose, and high-dose BSHXD groups were treated with BSHXD at doses of 5, 10, and 20 g/kg, respectively, once daily. The positive group was administered Alendronate (2.5 mg/kg) once daily. The Sham and Model groups were administered distilled water only. Intragastric administration was conducted once daily for a continuous 12-week period.

2.5. Micro-CT

Following 12 weeks after ovariectomy, the right femurs of all rats were extracted and subjected to micro-CT scanning. The scanning encompassed the distal to middle femur, comprising 600 layers, with each layer having a thickness of 10 μm. The scanning parameters were set as: voltage 55 kV, current 100 mA, and scanning time 14 min. The Nrecon software was utilized to generate 3D visualization images. Subsequently, bone static histomorphometry analysis was conducted to assess the trabecular bone parameters and cortical bone area.

2.6. Histological analysis

Histological analysis was conducted on right femur specimens. The specimens were fixed in 4% paraformaldehyde for 3 consecutive days. This was followed by decalcification in a solution of 4% ethylenediaminetetraacetic acid at a temperature of 10℃ for 28 d. The fixed tissues were dehydrated and were embedded in paraffin to cut 5-μm-thick sections. The sections were then deparaffinized and rehydrated, subsequently stained using hematoxylin and eosin (HE) as well as TRAP. The HE staining utilized the HE staining kit (Leagene, Beijing, China) following the standard protocol. For TRAP staining, the specimens underwent treatment using the TRAP staining kit (Wako, Osaka, Japan) and TRAP positive cells were counted microscopically.

2.7. Immunohistochemical (IHC) staining

MMP9, NFATc1, and Sirt1 expressions were detected by IHC analysis. The bone sections were incubated overnight at 4 ℃ with primary antibodies, including MMP9 (ab76003, abcam, Cambridge, UK, 1∶1000), NFATc1 (ab25916, abcam, Cambridge, UK, 1∶20), and Sirt1 (8469S, CST, Danvers, MA, USA, 1∶400). The following day, the sections were incubated with secondary antibodies, namely anti-rabbit immunoglobulin G (IgG) (H + L) (14708, 1∶5000), anti-mouse IgG (H + L) (14709, 1∶5000) for 1 h and the colour was developed with 3,3’-diaminobenzidine. Afterwards, the sections were counterstained with hematoxylin and pictures of the immunostaining were captured.

2.8. Preparation of drug-containing serum

A total of twenty Sprague-Dawley rats were divided into the control group and the drug group. The drug group received an oral administration of BSHXD at a dose of 20 g/kg twice daily, whereas the control group rats were orally administered an equal amount of saline. Following a 7-d treatment period, the rats were euthanized 2 h following the last dose. Blood samples were collected aseptically from the abdominal aorta of both groups and subsequently centrifuged to separate the serum. The obtained serum was then passed through a 0.22 μm filtration membrane and stored at -80 ℃.

2.9. Cell culture

The RAW 264.7 cells were acquired from Fudan Institute of Biomedical Sciences Cell Center (Shanghai, China) and cultured in dulbecco’s modified eagle medium (DMEM), which was supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The cell cultures were maintained in a controlled environment with 5% CO2 and 95% humidity at a temperature of 37 ℃. For osteoclast differentiation, the cells were cultured in a 96-well tissue culture plate until they adhered and reached a confluence of approximately 70%-80%. Following this, the culture medium was added with RANKL (50 ng/mL) and M-CSF (30 ng/mL) for osteoclast generation. After 5 d, osteoclastogenesis was assessed by examining cell morphology and performing TRAP staining.

2.10. Cell grouping and intervention

For various interventions, six groups of RAW 264.7 cells were established as follows: control group (complete medium), RANKL group, BSHXD low concentration group (5% BSHXD-containing serum), BSHXD medium concentration group (10% BSHXD-containing serum), and BSHXD high concentration group (15% BSHXD-containing serum).

To further investigate the role of Sirt1 in BSHXD-mediated protection. RAW264.7 were intervened with Sirtinol (Sirt1 inhibitor) alone or high concentration BSHXD alone or Sirtinol combined with high concentration BSHXD. The cells were subsequently categorized into six groups: control group, RANKL group, RANKL + BSHXD-H group, RANKL + Sirtinol group, and RANKL + Sirtinol + BSHXD-H group.

2.11. Cell viability assay

The RAW 264.7 cells were plated in 96-well plates and exposed to various concentrations of BSHXD-containing serum for 24 h. Following this, the cells were subjected to treatment using MTT solution (5 mg/mL). The supernatant was then removed and dimethyl sulfoxide (150 μL/well) to dissolve the formazan crystals. Finally, the optical density (OD) at 490 nm was recorded by a microporous plate.

2.12. Western blot

Total proteins of osteoclasts and bone tissues were extracted by radioimmunoprecipitation assay buffer. The supernatant was collected by centrifugation at 4 ℃ and 12000 rpm for 10 min, and the protein concentration in the sample was detected by the bicinchoninic acid (BCA) kit. Afterward, the lysates were separated by 8%-12% Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. To prevent nonspecific binding, the membranes were blocked with skim milk. Following this, overnight incubation at 4 ℃ using the following primary antibodies: NFATc1 (ab2796, abcam, Cambridge, UK, 1∶1000), Ctsk (57056, CST, 1∶1000), Oscar (ab209484, abcam, Cambridge, UK, 1∶1000), Trap (ab52750, abcam, Cambridge, UK, 1∶1000), p65 (ab32536, abcam, Cambridge, UK, 1∶1000), Sirt1 (ab110304, abcam, Cambridge, UK, 1∶1000), β-actin (4970, CST, Danvers, MA, USA, 1∶1000), Lamin B (17416, CST, Danvers, MA, USA, 1∶1000). After washing, the membrane was exposed to horseradish peroxidase-labeled secondary antibodies for 1.5 h. Eventually, Image J software was performed to quantify the grey-scale values.

2.13. Real-Time quantitative polymerase chain reaction (RT-qPCR)

The extraction of mRNA was conducted by TRNzol Universal Reagent, and the cDNA was reverse-transcribed from 1 µg of total RNA by the PrimeScript RT Master Mix kit (Takara, Shiga, Japan). Quantitative analysis of the expression of NFATc1 mRNA level was conducted by the SYBR Green PCR kit. The primer sequences used for PCR were as follows: Rattusnor-vegicus (RAT)-NFATc1 (Forward): GGGCATCTCAG-CTGTTCCTT, (Reverse): GCAGGGTTGCTGTAGA-TGGT. RAT-Glyceraldehyde-3-phosphate dehy-drogenase (GAPDH) (Forward): GGTGAAGGTCGGT-GTGAACG, (Reverse): CTCGCTCCTGGAAGATG-GTG. Mus musculus (MUS)-NFATc1 (Forward): CCAGCTTTCCAGTCCCTTCC, (Reverse): AGGTGA-CACTAGGGGACACA. MUS-GAPDH (Forward): GGCATGGACTGTGGTCATGA, (Reverse): TTCAC-CACCATGGAGAAGGC.

2.14. Immunofluorescence analysis

The RAW 264.7 cells were fixed in 4% paraformaldehyde for 20 min, followed by a 30-min blockage using 3% BSA. Next, the cells were incubated with the primary antibody Sirt1 (8469S, CST, Danvers, MA, USA, 1∶400) overnight and then with the secondary antibodies (1∶5000) for 1 h. The nuclei were stained with 4',6-diamidino-2-phenylindole. Finally, the fluorescent microscope was employed for visualization and photography of the tissue.

2.15. Luciferase assay

The RAW 264.7 cells were planted in 24-well plates and then transfected with 0.5 μg plasmid nuclear factor-kappa B luciferase plasmid as a control using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). The cells were pretreated with BSHXD-containing serum at concentrations of 0, 5%, 10%, 15%, 20%, 25% for 1 h and then exposed to RANKL (50 ng/mL). After 24 h, we detected the luciferase activity of NF-κB using a luciferase reporter assay kit (Promega Corporation, WI, USA).

2.16. Co-immunoprecipitation (Co-IP) analysis

The collected cells were subjected to cell lysis using a moderate amount of cell lysis buffer to extract the total protein. The total protein concentration was determined using a BCA protein assay kit. The samples were incubated with the specific primary antibodies p65 (ab32536, abcam, Cambridge, UK, 1∶1000), Sirt1 (ab110304, abcam, Cambridge, UK, 1∶1000) or IgG at 4 ℃, and then protein A/G-agarose beads was added to the sample mixtures and incubated at 4 ℃ with rotational agitation for 2 h. Following the immunoprecipitation reaction, the protein-antibody complex was centrifuged at 3000 rpm for 3 min, and then agarose beads were washed 3 times with Elution Buffer. Finally, the protein complexes were denatured by boiling in a 95 ℃ water bath for 5 min and subsequently analyzed by Western blot.

2.17. Statistical analyses

Data are presented as mean ± standard deviation. Data analysis was conducted using GraphPad Prism 8 (GraphPad software, San Diego, CA, USA), and differences among the treatment groups were compared using one-way analysis of variance with Tukey’s multiple comparison tests. A P value < 0.05 was considered statistically significant.

3. RESULTS

3.1. Phytochemical analysis of BSHXD

We used HPLC analysis to simultaneously determine the five major components in the extract of BSHXD, including Martynoside (0.22 mg/g), Hydroxysafflor yellow A (0.35 mg/g), Hyperoside (0.017 mg/g), Acteoside (0.011 mg/g), and Psoralen (0.013 mg/g) which were Martynoside, Hydroxysafflor yellow A, Hyperoside, Acteoside, and Psoralen. The retention time of the standard and BSHXD samples was shown in supplementary Figure 1.

3.2. Effect of BSHXD on bone loss in osteoporosis model rats

To evaluate the therapeutic effect of BSHXD in vivo, an osteoporosis model was established by surgically removing the ovaries of rats. Femur samples were collected from each group and subjected to micro-CT analysis. The results indicated that BSHXD treatment effectively alleviated the bone loss and bone trabecular destruction induced by OVX (Figure 1A). Subsequent analysis of the image parameters confirmed that the BSHXD-M and BSHXD-H groups exhibited a significant improvement in bone mineral density (BMD), trabecular number (Tb.N), trabecular thickness (Tb.Th), bone volume fraction (BV/TV) index, and a reduction in the trabecular separation (Tb.Sp) index compared to the OVX group (P < 0.01) (Figures 1B-1F). To further examine the impact of BSHXD on bone structure, HE staining was conducted. As depicted in Figures 1G, the OVX group exhibited a decrease in trabecular number, destruction of the reticular structure, and an increase in trabecular spaces compared to the sham group. Conversely, BSHXD administration resulted in a reduced bone marrow cavity, thickened trabecular bones, and compacted bone structure.

Figure 1. Effect of BSHXD on bone loss in osteoporosis model rats.

Figure 1

A: micro-CT with 3D reconstruction was performed, and representative images from each group are displayed; B: quantitative analysis of BMD of femurs; C: quantitative analysis of Tb.N of femurs; D: quantitative analysis of Tb.Th of femurs; E: quantitative analysis of BV/TV of femurs; F: D: quantitative analysis of Tb.Sp of femurs; G: representative HE staining images of femurs from rats (scale bars: 250 μm); A1, A7, G1: sham group; A2, A8, G2: OVX group; A3, A9, G3: BSHXD-L; A4, A10, G4: BSHXD-M; A5, A11, G5: BSHXD-H; A6, A12, G6: Alendronate group. Sham group: the rats received distilled water once every day for 12 weeks; Model group: the rats received distilled water once every day for 12 weeks; BSHXD-L group: the rats received BSHXD at a dose of 5 g/kg once every day for 12 weeks; BSHXD-M group: the rats received BSHXD at a dose of 10 g/kg once every day for 12 weeks; BSHXD-H group: the rats received BSHXD at a dose of 20 g/kg once every day for 12 weeks; Alendronate group: the rats received Alendronate at a dose of 2.5 mg/kg once every day for 12 weeks. BSHXD: Bushen Huoxue decoction; HE: hematoxylin and eosin; OVX: ovariectomized; BMD: bone mineral density; Tb.N: trabecular number, Tb.Th: trabecular thickness; BV/TV: bone volume fraction index; Tb.Sp: trabecular separation. The results are presented as the mean ± standard deviation (n = 6). Statistical analyses were measured using one-way analysis of variance with Tukey’s multiple comparison tests. aP < 0.05, compared to the sham group; bP < 0.05, compared to the OVX group.

3.3. BSHXD inhibited osteoclastogenesis in OVX-induced osteoporosis model rats

TRAP staining indicated that the number of osteoclasts (TRAP-positive cells) increased dramatically in the OVX group (P < 0.01). However, administration of BSHXD noticeably inhibited osteoclast formation and reduced the osteoclast count (P < 0.01), further providing additional evidence of the protective effects of BSHXD against bone loss (Figures 2A, 2B). Moreover, IHC analysis indicated that MMP9 and NFATc1 expressions were both increased in the OVX group (P < 0.01), whereas the BSHXD-M and BSHXD-H groups exhibited a dose-dependent reduction in the level of MMP9 and NFATc1 (P < 0.01) (Figures 2C-2E). These results provided convincing evidence for the potential of BSHXD in modulating bone loss via the inhibition of osteoclastogenesis and the prevention of osteoclast-mediated bone resorption.

Figure 2. BSHXD inhibited osteoclastogenesis in OVX-induced osteoporosis model rats.

Figure 2

A: representative TRAP staining images of femurs from rats (scale bars: 100 μm); B: quantitative analysis of TRAP staining images of femurs from rats; C: representative immunohistochemistry staining images of MMP9 and NFATc1 in the femur (scale bars: 100 μm); D: quantitative analysis of MMP9 in the femur; E: quantitative analysis of NFATc1 in the femur; A1, C1, C7: sham group; A2, C2, C8: OVX group; A3, C3, C9: BSHXD-L; A4, C4, C10: BSHXD-M; A5, C5, C11: BSHXD-H; A6, C6, C12: Alendronate group. Sham group: the rats received distilled water once every day for 12 weeks; Model group: the rats received distilled water once every day for 12 weeks; BSHXD-L group: the rats received BSHXD at a dose of 5 g/kg once every day for 12 weeks; BSHXD-M group: the rats received BSHXD at a dose of 10 g/kg once every day for 12 weeks; BSHXD-H group: the rats received BSHXD at a dose of 20 g/kg once every day for 12 weeks; Alendronate group: the rats received Alendronate at a dose of 2.5 mg/kg once every day for 12 weeks. BSHXD: Bushen Huoxue decoction; OVX: ovariectomized; Trap: tartrate-resistant acid phosphatase; MMP9: matrix metalloproteinase 9; NFATc1: nuclear factor of activated T cells cytoplasmic 1. The results are presented as the mean ± standard deviation (n = 3). Statistical analyses were measured using one-way analysis of variance with Tukey’s multiple comparison tests. aP < 0.05, compared to the sham group; bP < 0.05, compared to the OVX group.

3.4. BSHXD inhibited expression of osteoclast-specific proteins in femur tissue

To explore the influence of BSHXD on osteoclast differentiation, we performed a western blot to assess the level of osteoclast-related proteins. The results revealed an elevation in NFATc1 protein expression in the OVX group (P < 0.01), which was subsequently reduced in a dose-dependent manner following BSHXD treatment (supplementary Figures 2A). Additionally, Ctsk, Oscar, and Trap, which are downstream regulators of NFATc1 and play crucial roles in osteoclastogenesis, were found to be upregulated in the OVX group and significantly downregulated in the BSHXD medium and high dose groups (P < 0.01) based on western blot analysis (supplementary Figures 2B-2E).

3.5. BSHXD inhibited the activation of NF-κB by targeting SIRT1

Next, we further examined the transcriptional and translational levels of NFATc1. The results indicated that the NFATc1 gene expression was upregulated in the OVX group (P < 0.01). Conversely, after BSHXD treatment, there was a notable downregulation of NFATc1 gene expression (P < 0.01) (Figures 3A). To reveal the mechanism of BSHXD inhibits osteoclast differentiation, the activity of NF-κB signaling was further detected. As presented in Figures 3B, 3C, the acetylation level of the p65 subunit of NF-κB was markedly upregulated in the OVX group (P < 0.01), whereas BSHXD resulted in a downregulation of p65 acetylation (P < 0.01). Previous studies have reported that Sirt1 deacetylates p65 at lysine 310 to inhibit the NF-κB pathway.15 Therefore, we further investigated the influence of BSHXD on Sirt1 activity. As depicted in Figures 3D, 3E, the expression of Sirt1 was considerably decreased in the OVX group (P < 0.01), whereas were increased by BSHXD treatment in the BSHXD-M group and BSHXD-H group (P < 0.01). Moreover, western blot confirmed that BSHXD markedly upregulated the protein expression of Sirt1 in the nucleus (P < 0.01) (Figures 3F, 3G). Based on these results, we proposed that BSHXD may exert its suppressive effects on osteoclast differentiation in OVX-induced osteoporosis rat model by inhibiting NF-κB activation through targeting Sirt1.

Figure 3. BSHXD inhibited the activation of NF-κB by targeting SIRT1.

Figure 3

A: quantification of gene expression of NFATc1; B: the expression of p65-Acetyl310 was detected via Western blot; C: relative protein expression levels of p65-Acetyl310; D: representative immunohistochemistry staining images of SIRT1 in the femur (scale bars: 100 μm); E: quantitative analysis of SIRT1 in the femur; F: the expression of SIRT1 was detected via Western blot; G: relative protein expression levels of SIRT1; D1: sham group; D2: OVX group; D3: BSHXD-L; D4: BSHXD-M; D5: BSHXD-H. Sham group: the rats received distilled water once every day for 12 weeks; Model group: the rats received distilled water once every day for 12 weeks; BSHXD-L group: the rats received BSHXD at a dose of 5 g/kg once every day for 12 weeks; BSHXD-M group: the rats received BSHXD at a dose of 10 g/kg once every day for 12 weeks; BSHXD-H group: the rats received BSHXD at a dose of 20 g/kg once every day for 12 weeks. BSHXD: Bushen Huoxue decoction; OVX: ovariectomized; SIRT1: Sirtuin 1; p65: nuclear factor NF-kappa-B p65 subunit. The results are presented as the mean ± standard deviation (n = 3). Statistical analyses were measured using one-way analysis of variance with Tukey’s multiple comparison tests. aP < 0.05, compared to the sham group; bP < 0.05, compared to the OVX group.

3.6. BSHXD suppressed RANKL-induced osteoclast differentiation

In this study, RAW264.7 cells were exposed to different concentrations of BSHXD-containing serum. The MTT assay was performed to evaluate the effect of BSHXD on RAW264.7 viability. Our results demonstrated that BSHXD-containing serum did not exhibit cytotoxicity in RAW264.7 cells at concentrations up to 15% (supplementary Figures 3A). Thus, we selected this serum concentration for further experiments.

To evaluate the influence of BSHXD on the differentiation of osteoclasts induced by RANKL, we applied different concentrations of BSHXD-containing serum (5%, 10%, 15%) to stimulate RAW264.7 cells. TRAP staining indicated that the RANKL group exhibited numerous and large osteoclasts, whereas the BSHXD treatment group had significantly lower and smaller osteoclasts (P < 0.01), indicating BSHXD effectively inhibits osteoclast formation (supplementary Figures 3B, 3C). Additionally, we evaluated the protein expression of NFATc1 to ensure the concordance between our in vitro and in vivo models. In the Western blot analysis, it was observed that the RANKL group exhibited a notable elevation in NFATc1 levels (P < 0.01). Nevertheless, when BSHXD-containing serum was administered, a remarkable decrease in the expression of NFATc1 was observed (P < 0.01) (supplementary Figures 3D, 3E).

3.7. BSHXD promotes the deacetylation of p65 and inhibited NF‐κB activity in vitro

Further investigation was performed to explore the impact of BSHXD on NF-κB activity in vitro. The findings indicated that the gene level of NFATc1 was upregulated following RANKL induction (P < 0.01), while BSHXD markedly downregulated the gene level of NFATc1 in a concentration-dependent decrease (P < 0.01) (supplementary Figure 4A). Moreover, the dual luciferase reporter assay provided evidence that both the medium and high BSHXD concentration groups significantly inhibited NF-κB activity (supplementary Figure 4B). As presented in supplementary Figures 4C, 4D, the acetylation level of the p65 subunit of NF-κB was raised in the RANKL group (P < 0.01), whereas BSHXD led to a notable reduction in the acetylation level of p65 (P < 0.01). These findings suggested that BSHXD inhibited NF‐κB activity by promoting the deacetylation of p65.

3.8. BSHXD inhibits osteoclastogenesis by activating SIRT1

SIRTI was identified to inhibit osteoclast differentiation, and several studies have demonstrated that Sirt1 regulates RANKL-stimulated NF-κB signaling during osteoclastogenesis.17 Therefore, we explored whether BSHXD regulates Sirt1 activity during RANKL-induced osteoclastogenesis. The immunofluorescence results revealed that the Sirt1 expression was decreased in the RANKL group (P < 0.01), whereas was markedly reversed in medium and high BSHXD concentration groups (P < 0.01) (Figures 4A, 4B). Moreover, western blot results were consistent with immunofluorescence findings, which indicated that the presence of BSHXD-containing serum substantially upregulated the level of Sirt1 in a concentration-dependent manner (Figure 4C). Furthermore, CO-IP assay provided evidence that BSHXD promotes the binding of Sirt1 to p65 in a concentration-dependent manner (Figures 4D, 4E). These findings implied that BSHXD may inhibit osteoclast differentiation through the activation of Sirt1.

Figure 4. BSHXD inhibits osteoclast differentiation by activating SIRT1.

Figure 4

A: representative immunofluorescence staining images of SIRT1 (scale bars: 50 μm; green: SIRT1; blue: DAPI); B: quantitative analysis of immunofluorescence staining images of SIRT1; C: the protein expression level of SIRT1 was detected via Western blot; D: the protein expression level of p65 and SIRT1 were detected via Western blot; E: relative protein expression levels of p65/SIRT1; A1, A6, A11: Control group; A2, A7, A12: RANKL group; A3, A8, A13: BSHXD-L group; A4, A9, A14: BSHXD-M group; A5, A10, A15: BSHXD-H group. Control group: RAW 264.7 cells cultured with 30 ng/mL M-CSF; RANKL group: RAW 264.7 cells cultured with 50 ng/mL RANKL and 30 ng/mL M-CSF; BSHXD-L group: RAW 264.7 cells cultured with 50 ng/mL RANKL, 30 ng/mL M-CSF, and 5% BSHXD-containing serum; BSHXD-M group: RAW 264.7 cells cultured with 50 ng/mL RANKL, 30 ng/mL M-CSF, and 10% BSHXD-containing serum; BSHXD-H group: RAW 264.7 cells cultured with 50 ng/mL RANKL, 30 ng/mL M-CSF, and 15% BSHXD-containing serum. BSHXD: Bushen Huoxue decoction; SIRT1: Sirtuin 1; p65: nuclear factor NF-kappa-B p65 subunit. The results are presented as the mean ± standard deviation (n = 3). Statistical analyses were measured using one-way analysis of variance with Tukey’s multiple comparison tests. aP < 0.05, compared to the control group; bP < 0.05, compared to the RANKL group.

3.9. Sirtinol inhibited the antagonistic effect of BSHXD to osteoclast differentiation

As shown in supplementary Figures 5A, 4B, the RANKL + BSHXD-H group exhibited lower and smaller osteoclasts than the RANKL group (P < 0.01). Following intervention with Sirtinol (Sirt1 inhibitor), we observed a notable elevation in the osteoclast count compared with the RANKL+BSHXD-H group (P < 0.01), further suggesting that BSHXD inhibits osteoclast differentiation through activation of SIRT1. Moreover, we found that the gene level of NFATc1 was downregulated in the RANKL + BSHXD-H group compared to the RANKL group. Nevertheless, after Sirtinol intervention, the expression level of NFATc1 significantly increased (P < 0.01) (supplementary Figures 5C). The dual luciferase reporter assay indicated that BSHXD markedly inhibits the NF-κB activity, while the RANKL + Sirtinol + BSHXD-H group exhibits higher NF‐κB activity than the RANKL + BSHXD-H group (P < 0.05) (supplementary Figure 5D), which suggested that upregulation of Sirt1 can effectively inhibit NF-κB activity. In addition, western blot demonstrated a decrease in the acetylation level of p65 in the RANKL+BSHXD-H group compared with the RANKL group (P < 0.01). However, after Sirtinol intervention, no significant change in the level of p65 acetylation was discovered in the presence or absence of BSHXD treatment, which suggested that the acetylation level of p65 is primarily regulated by Sirt1 (supplementary Figures 5E, 5F). Taken together, it is speculated that BSHXD upregulates Sirt1 expression, promotes p65 deacetylation, and subsequently inhibits NF-κB activation.

4. DISCUSSION

As women age and go through menopause, the rate of bone resorption outpaces bone formation, which results in fragile bones and an increased risk of fracture.24 Fractures related with PMOP can lead to significant pain, disability, and reduce quality of life.2 Hence, it is crucial to search for effective and safe drugs for PMOP treatment. Lately, there has been an increasing enthusiasm for exploring the potential of TCM to treat PMOP.13,25 BSHXD has been clinically used for many years to treat PMOP and has shown the ability to regulate hormone levels, enhance blood circulation, and improve bone metabolism. In the study, we observed that BSHXD could ameliorate OVX-induced bone loss in osteoporosis model rats based on micro-CT and histomorphometric analysis. Moreover, BSHXD could target Sirt1 to significantly inhibit the activity of NF-κB signaling through promoting p65 deacetylation. These findings uncovered BSHXD as a promising therapeutic approach to attenuating the development of PMOP by targeting specific molecular pathways.

BSHXD (a herbal formula) is composed of 11 herbs used in TCM and has a complex chemical composition. Based on the HPLC analysis, our experiments have shown that Martynoside, Hydroxysafflor yellow A, Hyperoside, Acteoside, and Psoralen are the most effective components of BSHXD. Notably, Hydroxysafflor Yellow A has been found to have the potential to enhance bone mineralization and inhibit bone resorption, thereby facilitating bone development and suppressing OVX-induced osteoporosis.26 Several studies have demonstrated that Hyperoside could improve bone microstructure and bone metabolism in OVX rats, and its underlying molecular mechanism may involve the suppression of the TRAF6 mediated NF-κB pathways.27 Moreover, it has been shown that Psoralen, the main pharmacodynamic component of P. corylifolia, exhibits antiestrogenic activity, antioxidant activity, and antiosteoporosis effect.28,29 And Psoralen has also been proven to ameliorate OVX-induced osteoporosis by inhibiting osteoclast activity and differentiation through the inactivation of the NF-κB, phosphoinositide 3-kinase/protein kinase B, and JNK/MAPK signaling.30 The above reports provided compelling evidence for the potential of BSHXD in attenuating osteoporosis. In our study, micro-CT analysis showed that BSHXD treatment increased BMD and bone volume fraction compared to the OVX group. In addition, TRAP staining indicated that BSHXD decreased osteoclast numbers surrounding the trabecula in OVX rats. These findings indicated that BSHXD exhibits anti-osteoporosis activity and can effectively increase the BMD, improve the bone microarchitecture, and prevent bone loss.

Bone is a dynamically tissue that maintains its mineralized balance and structural integrity through continuous remodeling.31 In PMOP, the bone formation-resorption balance is disrupted. Hyperactivated osteoclasts first attach to the bone surface, forming a bone resorptive microenvironment. Subsequently, these cells secrete enzymes that are capable of acid degradation, which leads to bone micro-structural damage and accelerates bone loss.32 Consequently, the primary approach to prevent PMOP is to mitigate abnormal osteoclast differentiation. Results of in vitro studies showed that BSHXD suppresses RANKL-induced osteoclastogenesis and reduces the count of TRAP-positive cells and osteoclasts. NFATc, a crucial regulator for osteoclast differentiation and activity, mediates the expression of osteoclast-related genes.33,34 Our study revealed that BSXHD treatment decreases the gene and protein expression of NFATc1, which correspondingly resulted in the downregulation of its downstream osteoclast-specific genes. Therefore, we speculated that BSHXD suppresses bone resorption is through the inhibition of osteoclast differentiation.

It is well known that MCSF and RANKL are two indispensable cytokines in the process of osteoclast formation.35,36 The binding of RANKL and RANK led to the recruitment of TRAF6, which triggers downstream NF-κB signal pathways.37 The activation of NF-κB is a crucial initial signaling events induced by RANKL, and disruptions in this signaling axis suppress osteoclastogenesis in vitro and result in bone loss in vivo.38 And the NF-κB family of signaling molecules regulate osteoclast differentiation and function through a complex protein regulatory system to maintain normal bone mass.39 Furthermore, the control of NF-κB activity involves complex and highly regulated mechanisms, in which the acetylation of the p65 subunit is a significant factor in regulating its transcriptional activity.40 In our study, the results demonstrated that BSHXD significantly reduced NF‐κB activity and the acetylation level of p65 subunit of NF-κB. Thus, the suppression of NF-κB activity via reducing Lys310 acetylation of p65 may be the mechanism by which BSHXD suppresses osteoclast differentiation.

Notably, the acetylation of NF-κB p65 is regulated by histone deacetylases (HDACs), which inhibit gene expression by removing acetyl groups from transcription factors.41 The activation of the RANKL-mediated NF-κB signaling has been found to involve multiple HDACs such as Sirt1, HDAC3, and HDAC5.42,43 Sirt1, an NAD+-dependent histone deacetylase,44 plays a crucial role in controlling diverse biological processes such as mitochondrial homeostasis, energy metabolism, cellular aging, and cell death.45,46 Chen et al47 reported that Sirt1-knockout mice show a low bone mass phenotype, and the bone formation in mice was promoted upon treatment with SIRT1 activators. Similarly, Feng et al 48 revealed that Sirt1 inhibits the level of p65 in the NF-κB signaling, and thus prevents osteoclast differentiation, ultimately inhibiting the development of osteoporosis. Moreover, SIRT1 forms a complex with the acetyltransferase P300, which inhibits RANKL-induced p65 acetylation and subsequently deacetylates P65 at the 310 lysine position, further suppressing the NF-κB pathway.15 In our study, it was found that the upregulation of Sirt1 by BSHXD suppresses RANKL-induced p65 acetylation. And the CO-IP assay indicated that BSHXD promotes the binding of Sirt1 to p65 in a concentration-dependent manner. Furthermore, intervention with Sirtinol (Sirt1 inhibitor) reversed BSHXD-induced p65 deacetylation and counteracted the inhibitory effects on RANKL-mediated osteoclast differentiation and function. These results collectively suggested that BSHXD inhibits NF-κB activity by upregulating Sirt1 to promote p65 deacetylation.

This study provided the first evidence that BSHXD attenuates osteoclastogenesis and prevents bone loss through the Sirt1/NF-κB signaling pathway. These findings uncovered a novel mechanism underlying the anti-osteoporotic effects of BSHXD and highlight its potential as a multi-target therapeutic agent for PMOP. By establishing a clear link between the bioactive constituents of BSHXD and a specific signaling pathway, this work integrates TCM with contemporary molecular pharmacology, supporting the translational value of BSHXD in evidence-based medicine. However, there were several limitations of this study. First, BSHXD is a TCM compound comprising 11 different herbs, which poses a challenge in identifying the specific active components responsible for the observed effects. Secondly, the study primarily focused on the short-term impacts of BSHXD on bone health. However, it would be valuable to evaluate the long-term effects and safety profile of BSHXD, particularly in chronic administration, to evaluate its suitability for prolonged use in managing PMOP. Finally, BSHXD comprises a blend of different Chinese medicines with numerous targets and action mechanisms. The impact of BSHXD on bone loss may involve additional molecular pathways or targets, necessitating further investigation.

In conclusion, our findings suggested that BSHXD suppresses osteoclast formation by targeting Sirt1 mediated NF-κB pathway activation, thus inhibiting bone loss in OVX rats. These findings emphasized the potential value of TCM in the management of osteoporosis and offered an experimental rationale for the clinical treatment of PMOP patients with BSHXD.

5. SUPPORTING INFORMATION

Supporting data to this article can be found online at http://www.journaltcm.com.

JTCM-46-5-1127-S8.pdf (941.4KB, pdf)

Contributor Information

Lan WU, Email: 920919625@qq.com.

Zhiwei LI, Email: fsyy00797@njucm.edu.cn.

REFERENCES

  • [1]. Hatano M, Sasabuchi Y, Okada A, et al. . Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study. Ann Rheum Dis 2025; 84: 1938-47. [DOI] [PubMed] [Google Scholar]
  • [2]. Crandall CJ, Larson JC, Schousboe JT, et al. . Race and ethnicity and fracture prediction among younger postmenopausal women in the women's health initiative study. JAMA Intern Med 2023; 183: 696-704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3]. Zheng HW, Bui AAT, Ensrud KE, et al. . Identifying younger postmenopausal women with osteoporosis using USPSTF-recommended osteoporosis risk assessment tools. JAMA Netw Open 2025; 8: e250626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4]. Aga R, Søgaard AJ, Holvik K, et al. . Effectiveness of a fall and fracture prevention pathway on hip fracture risk, need of permanent care and mortality: a controlled before-and-after study. Age Ageing 2025; 54: afaf161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5]. Cotts KG, Cifu AS. . Treatment of osteoporosis. JAMA 2018; 319: 1040-1. [DOI] [PubMed] [Google Scholar]
  • [6]. Qaseem A, Forciea MA, McLean RM, et al. . Treatment of low bone density or dsteoporosis to prevent fractures in men and women: a clinical practice guideline update from the american college of physicians. Ann Intern Med 2017; 166: 818-39. [DOI] [PubMed] [Google Scholar]
  • [7]. Crandall CJ, Newberry SJ, Diamant A, et al. . Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161: 711-23. [DOI] [PubMed] [Google Scholar]
  • [8]. Eriksen EF. . Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010; 11: 219-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Zhi X, Wang L, Chen H, et al. . l-tetrahydropalmatine suppresses osteoclastogenesis in vivo and in vitro via blocking RANK-TRAF6 interactions and inhibiting NF-κB and MAPK pathways. J Cell Mol Med 2020; 24: 785-98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10]. Zainabadi K. . Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders? Pharmacol Res 2019; 143: 97-105. [DOI] [PubMed] [Google Scholar]
  • [11]. Boyle WJ, Simonet WS, Lacey DL. . Osteoclast differentiation and activation. Nature 2003; 423: 337-42. [DOI] [PubMed] [Google Scholar]
  • [12]. Zeng J, Guo J, Sun Z, Deng F, Ning C, Xie Y. . Osteoblastic and anti-osteoclastic activities of strontium-substituted silicocarnotite ceramics: In vitro and in vivo studies. Bioact Mater 2020; 5: 435-46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13]. Idris AI, Krishnan M, Simic P, et al. . Small molecule inhibitors of IkappaB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. Faseb J 2010; 24: 4545-55. [DOI] [PubMed] [Google Scholar]
  • [14]. Sun P, Huang T, Huang C, Wang Y, Tang D. . Role of histone modification in the occurrence and development of osteoporosis. Front Endocrinol (Lausanne) 2022; 13: 964103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15]. Shakibaei M, Buhrmann C, Mobasheri A. . Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappa B signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 2011; 286: 11492-505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16]. Edwards JR, Perrien DS, Fleming N, et al. . Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res 2013; 28: 960-9. [DOI] [PubMed] [Google Scholar]
  • [17]. Zhao L (Qing dynasty). Shang Ke Da Cheng. Shanghai: Shanghai Classics Publishing House, 1995: 45- 50. [Google Scholar]
  • [18]. Zhang ND, Han T, Huang BK, et al. . Traditional Chinese medicine formulas for the treatment of osteoporosis: implication for antiosteoporotic drug discovery. J Ethnopharmacol 2016; 189: 61-80. [DOI] [PubMed] [Google Scholar]
  • [19]. Zhan JW, Li KM, Zhu LG, et al. . Efficacy and safety of Bushen Huoxue Formula in patients with discogenic low-back pain: a double-blind, randomized, placebo-controlled trial. Chin J Integr Med 2022; 28: 963-70. [DOI] [PubMed] [Google Scholar]
  • [20]. Zhang XJ, Zhang XL, Wu ZP, Nie J, Xiong JF. . Effect of Busheng Huoxue capsule on the quality of life of primary osteoporosis senile males. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2014; 34: 292-6. [PubMed] [Google Scholar]
  • [21]. Hu S, Ge Q, Xia C, et al. . Bushenhuoxue formula accelerates fracture healing via upregulation of TGF-β/Smad2 signaling in mesenchymal progenitor cells. Phytomedicine 2020; 76: 153256. [DOI] [PubMed] [Google Scholar]
  • [22]. Chen S, Tao L, Zhu F, et al. . BushenHuoxue decoction suppresses M1 macrophage polarization and prevents LPS induced inflammatory bone loss by activating AMPK pathway. Heliyon 2023; 9: e15583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23]. Reagan-Shaw S, Nihal M, Ahmad N. . Dose translation from animal to human studies revisited. Faseb j 2008; 22: 659-61. [DOI] [PubMed] [Google Scholar]
  • [24]. Yi H, Zhang N, Sundquist J, Sundquist K, Zheng X, Ji J. . Long-term outcomes after unilateral salpingo-oophorectomy: a registry-based retrospective cohort study. PLoS Med 2025; 22: e1004639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25]. Feng YC, Liu YL, Dang X, et al. . Exploring the multicomponent synergy mechanism of Zuogui Wan on postmenopausal osteoporosis by a systems pharmacology strategy. J Tradit Chin Med 2024; 44: 489-95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Kanis JA, Cooper C, Rizzoli R, Reginster JY. . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30: 3-44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27]. Wang P, Wang M, Zhuo T, et al. . Hydroxysafflor yellow A promotes osteogenesis and bone development via epigenetically regulating β-catenin and prevents ovariectomy-induced bone loss. Int J Biochem Cell Biol 2021; 137: 106033. [DOI] [PubMed] [Google Scholar]
  • [28]. Chen Y, Dai F, He Y, et al. . Beneficial effects of hyperoside on bone metabolism in ovariectomized mice. Biomed Pharmacother 2018; 107: 1175-82. [DOI] [PubMed] [Google Scholar]
  • [29]. Ren Y, Song X, Tan L, et al. . A review of the pharmacological properties of psoralen. Front Pharmacol 2020; 11: 571535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30]. Lu Y, Zhang M, Zhang J, Jiang M, Bai G. . Psoralen prevents the inactivation of estradiol and treats osteoporosis via covalently targeting HSD17B2. J Ethnopharmacol 2023; 311: 116426. [DOI] [PubMed] [Google Scholar]
  • [31]. Ren P, Wang QW, Bai W, et al. . Identifying the effective combination of acupuncture and traditional Chinese medicinal herbs for postmenopausal osteoporosis therapy through studies of their molecular regulation of bone homeostasis. J Tradit Chin Med 2024; 44: 212-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32]. Li F, Li Q, Huang X, et al. . Psoralen stimulates osteoblast proliferation through the activation of nuclear factor-κB-mitogen-activated protein kinase signaling. Exp Ther Med 2017; 14: 2385-91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33]. Mudri D, Kizivat T, Mihaljević I, Bilić Ćurčić I. . Wnt inhibitors and bone mineral density in patients with graves' disease treated with antithyroid drugs: a preliminary prospective study. Metabolites 2022; 12: 711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34]. Matsoukas MT, Aranguren-Ibáñez Á, Lozano T, et al. . Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners. Sci Signal 2015; 8: ra63. [DOI] [PubMed] [Google Scholar]
  • [35]. Huang XL, Huang LY, Cheng YT, et al. . Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med 2019; 44: 582-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36]. Yasuda H, Shima N, Nakagawa N, et al. . Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37]. Liu Y, Liu W, Yu Z, et al. . A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways. Cell Death Dis 2021; 12: 654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38]. Wang Z, Li Z, Wang G, Sun Y, Yuan Y, Nie H. . Salubrinal alleviates collagen-induced arthritis through promoting P65 degradation in osteoclastogenesis. Int J Mol Sci 2021; 22: 3501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39]. Wu Z, Li C, Chen Y, et al. . Chrysin protects against titanium particle-induced osteolysis by attenuating osteoclast formation and function by inhibiting NF-κB and MAPK signaling. Front Pharmacol 2022; 13: 793087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40]. Wu J, Li XY, Fang X, Teng FY, Xu Y. . Decreased serum maresin 1 concentration is associated with postmenopausal osteoporosis: a cross-sectional study. Front Med (Lausanne) 2021; 8: 759825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41]. Deqiang D, Yan X, Dan MA, et al. . Role of toll-like receptor 4/mutant myeloid differentiation primary response 88/nuclear factor kappa-B mediated inflammation in diabetes mellitus with Northwest dryness syndrome. J Tradit Chin Med 2024; 44: 963-73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [42]. Astleford K, Campbell E, Norton A, Mansky KC. . Epigenetic regulators involved in osteoclast differentiation. IJMS 2020; 21: 7080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43]. Kurotaki D, Yoshida H, Tamura T. . Epigenetic and transcriptional regulation of osteoclast differentiation. Bone 2020; 138: 115471. [DOI] [PubMed] [Google Scholar]
  • [44]. Finkel T, Deng CX, Mostoslavsky R. . Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [45]. Chen Y, Zhou F, Liu H, et al. . SIRT1, a promising regulator of bone homeostasis. Life Sci 2021; 269: 119041. [DOI] [PubMed] [Google Scholar]
  • [46]. Cohen-Kfir E, Artsi H, Levin A, et al. . Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 2011; 152: 4514-24. [DOI] [PubMed] [Google Scholar]
  • [47]. Chen H, Hu X, Yang R, et al. . SIRT1/FOXO3a axis plays an important role in the prevention of mandibular bone loss induced by 1,25(OH)(2)D deficiency. Int J Biol Sci 2020; 16: 2712-26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48]. Feng J, Liu S, Ma S, et al. . Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-κB signaling pathway. Acta Biochim Biophys Sin (Shanghai) 2014; 46: 1024-33. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting data to this article can be found online at http://www.journaltcm.com.

JTCM-46-5-1127-S8.pdf (941.4KB, pdf)

Articles from Journal of Traditional Chinese Medicine are provided here courtesy of Journal of Traditional Chinese Medicine

RESOURCES